CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, Chairman of the Department of Neurology at the University Hospital in Zurich and National Coordinating Investigator for CNS's Berubicin study. The segment focused on glioblastoma multiforme (GBM), discussing unmet medical needs, current treatments, and Berubicin's potential as a solution for this condition.
CNS Pharmaceuticals (NASDAQ:CNSP) ha annunciato la sua partecipazione a un segmento Virtual Investor KOL Connect con il Professor Michael Weller, Presidente del Dipartimento di Neurologia presso l'Ospedale Universitario di Zurigo e Investigatore Coordinatore Nazionale per lo studio di Berubicin di CNS. Il segmento si è concentrato sul glioblastoma multiforme (GBM), discutendo i bisogni medici insoddisfatti, i trattamenti attuali e il potenziale di Berubicin come soluzione per questa condizione.
CNS Pharmaceuticals (NASDAQ:CNSP) anunció su participación en un segmento Virtual Investor KOL Connect que contó con la presencia del Profesor Michael Weller, Presidente del Departamento de Neurología en el Hospital Universitario de Zúrich e Investigador Coordinador Nacional para el estudio de Berubicin de CNS. El segmento se centró en el glioblastoma multiforme (GBM), discutiendo las necesidades médicas no satisfechas, los tratamientos actuales y el potencial de Berubicin como solución para esta condición.
CNS Pharmaceuticals (NASDAQ:CNSP)는 취리히 대학병원 신경학과 주임인 마이클 웰러 교수와 함께하는 Virtual Investor KOL Connect 세그먼트에 참여한다고 발표했습니다. 이 세그먼트는 다형성 신경교종 (GBM)에 초점을 맞추어 의학적 요구, 현재 치료법 및 이 질환에 대한 해결책으로서의 Berubicin의 가능성에 대해 논의했습니다.
CNS Pharmaceuticals (NASDAQ:CNSP) a annoncé sa participation à un segment Virtual Investor KOL Connect avec le Professeur Michael Weller, Président du Département de Neurologie à l'Hôpital Universitaire de Zurich et Investigateur Coordinateur National pour l'étude Berubicin de CNS. Le segment s'est concentré sur le glioblastome multiforme (GBM), discutant des besoins médicaux non satisfaits, des traitements actuels et du potentiel de Berubicin comme solution à cette condition.
CNS Pharmaceuticals (NASDAQ:CNSP) gab seine Teilnahme an einem Virtual Investor KOL Connect-Segment bekannt, das Professor Michael Weller, den Vorsitzenden der Neurologie am Universitätsspital Zürich und nationalen koordinierenden Forscher der Berubicin-Studie von CNS, featured. Das Segment konzentrierte sich auf glioblastoma multiforme (GBM), wobei unerfüllte medizinische Bedürfnisse, aktuelle Behandlungen und das Potenzial von Berubicin als Lösung für diesen Zustand erörtert wurden.
- None.
- None.
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller
HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment.
As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
The Virtual Investor KOL Connect segment featuring CNS can be accessed here.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What did Professor Michael Weller discuss in CNS Pharmaceuticals' (CNSP) Virtual Investor KOL Connect segment?
What is Professor Michael Weller's role in CNS Pharmaceuticals' (CNSP) Berubicin study?
What is CNS Pharmaceuticals' (CNSP) focus area in drug development?
